XOMA Royalty (XOMA) and Takeda (TAK) stock in focus as the companies ink a new royalty deal and armed an existing agreement.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

DNA Ginkgo Bioworks Holdings, Inc.

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...